ARQT vs NVCR

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Analysts rate Arcutis Biotherapeutics, Inc. (ARQT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcutis Biotherapeutics, Inc.

(ARQT) delivered a total return of -39. 5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus ARQT's -5. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcutis Biotherapeutics, Inc.

(ARQT) is the lower-risk stock at 1. 48β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 49% more volatile than ARQT relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcutis Biotherapeutics, Inc.

(ARQT) is the more profitable company, earning -4. 3% net margin versus -20. 8% for NovoCure Limited — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARQT leads at -3. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ARQT: -5. 2%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ARQT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.